Glue, Not Chains: Teaching AI to Degrade Amyloid-β the Hard Way
Opening — Why this matters now For more than two decades, Alzheimer’s drug discovery has been trapped in a loop: identify amyloid, try to block it, fail clinically, repeat with better marketing. What has quietly changed is not our understanding of amyloid-β itself, but our tooling. Intracellular amyloid-β42 (Aβ42) is now widely seen as an early, toxic driver of disease—yet it remains structurally awkward, aggregation-prone, and resistant to classical inhibition strategies. ...